INTC vs LLY: Which Is the Better Buy?
Side-by-side comparison of Intel Corporation and Eli Lilly and Company — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-05-01.
Intel Corporation · Technology
$82.54
-5.4% upside to fair value
Grade D
VS
Eli Lilly and Company · Healthcare
$934.34
+17.6% upside to fair value
Grade B
High Quality
QuantHub Verdict
LLY has more upside to fair value
(+17.6%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
INTC |
LLY |
| Current Price |
$82.54 |
$934.34 |
| Fair Value Estimate |
$78.09 |
$1,098.43 |
| Upside to Fair Value |
-5.4%
|
+17.6%
|
| Market Cap |
$414.4B |
$882.8B |
| Forward P/E |
-132.2x
|
33.1x
|
| EV / EBITDA |
50.1x
|
27.9x
|
| Price / Sales |
7.7x
|
12.2x
|
| Price / FCF |
-132.9x
|
65.0x
|
| Revenue Growth YoY |
+7.2%
|
+55.5%
|
| Gross Margin |
35.4%
|
82.7%
|
| Operating Margin |
-9.4%
|
46.3%
|
| Return on Equity |
-3.0%
|
101.3%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
—
|
1.54%
|
| Analyst Consensus |
Hold
|
Strong Buy
|
Investment Thesis
Intel Corporation is a leading semiconductor company transitioning to a foundry business model while maintaining significant revenue from client computing and data center segments. Despite a strong market position and experienced leadership, the company faces earnings pressure with a 354% decline in earnings in the most recent quarter and negative margins. The stock trades at $82.54, which is 5.4…
Eli Lilly and Company is a leading global pharmaceutical firm with a dominant position in the diabetes and obesity markets, driven by its blockbuster GLP-1 drugs Mounjaro and Zepbound which generated $36.5 billion in FY2025. The company reported $65.2 billion in total revenue for 2025, making it the top pharma by revenue globally. It exhibits high business quality with a durable competitive moat …
Accumulation Zones
| Metric |
INTC |
LLY |
| Zone Low |
$58.57 |
$823.82 |
| Zone High |
$66.38 |
$933.67 |
| In Buy Zone? |
No
|
No
|